In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calistoga Pharmaceuticals, Inc.

http://www.calistogapharma.com

Latest From Calistoga Pharmaceuticals, Inc.

Orasis Prepares To Battle AbbVie In Presbyopia

The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.

Approvals Business Strategies

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Sales & Earnings Rare Diseases

Finance Watch: VC Mega-Rounds Make A Comeback In March

Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.

Financing Innovation

The Busiest Dealmakers Of 2022

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Outlook 2023 M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register